Study: CyberKnife benefits prostate cancer patients

By staff writers

October 1, 2009 -- Radiotherapy firm Accuray of Sunnyvale, CA, is touting the results of a study on early-stage prostate cancer patients treated with its CyberKnife radiosurgery system.

The study showed that erectile function was preserved in 81% of patients at a median follow-up of two years. Previous research on erectile function preservation at two years for other commonly used prostate cancer treatments, such as open surgery and conventional radiation therapy, has produced values ranging from 50% to 70%.

The study of 112 patients achieved 97% sustained response at two years, with urinary and rectal side-effect profiles comparable to conventional radiation therapy.

The study was published in Technology in Cancer Research and Treatment.

Accuray completes Illinois installation, July 24, 2009

Accuray gets 10th HCA install, June 24, 2009

Accuray touts CyberKnife milestone in Japan, March 19, 2009

Accuray grows revenue in Q2, January 30, 2009

Accuray notches 100th U.S. installation, December 24, 2008

Copyright © 2009


To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking